Successful treatment with nivolumab for lung cancer with low expression of PD-L1 and prominent tumor-infiltrating B cells and immunoglobulin G.
Thorac Cancer
; 9(6): 750-753, 2018 06.
Article
en En
| MEDLINE
| ID: mdl-29667757
ABSTRACT
Little is known about the anti-tumor activity of humoral immunity in lung cancer patients treated with nivolumab, an immune checkpoint inhibitor. Herein, we report a case of lung cancer with 5% expression of PD-L1, in which a partial response to nivolumab was sustained for > 7 months. Immunohistochemical analysis of the metastatic lymph node biopsy specimen showed prominent accumulation of plasma cells and immunoglobulin G. These findings suggest that pre-existing humoral immunity may be worth considering as a candidate therapeutic biomarker of nivolumab in some lung cancer patients.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Inmunoglobulina G
/
Antígeno B7-H1
/
Antineoplásicos Inmunológicos
/
Nivolumab
/
Neoplasias Pulmonares
Límite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Thorac Cancer
Año:
2018
Tipo del documento:
Article
País de afiliación:
Japón